| Cyclooxygenase‐independent actions of cyclooxygenase inhibitors I Tegeder, J Pfeilschifter, G Geisslinger The FASEB Journal 15 (12), 2057-2072, 2001 | 930 | 2001 |
| COX‐2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX‐2 inhibitor celecoxib S Grösch, I Tegeder, E Niederberger, L Bräutigam, G Geisslinger The FASEB journal 15 (14), 1-22, 2001 | 692 | 2001 |
| GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence I Tegeder, M Costigan, RS Griffin, A Abele, I Belfer, H Schmidt, C Ehnert, ... Nature medicine 12 (11), 1269-1277, 2006 | 652 | 2006 |
| Cyclooxygenase-2 (COX-2)–independent anticarcinogenic effects of selective COX-2 inhibitors S Grösch, TJ Maier, S Schiffmann, G Geisslinger Journal of the National Cancer Institute 98 (11), 736-747, 2006 | 616 | 2006 |
| Mutschler Arzneimittelwirkungen E Mutschler, G Geisslinger, HK Kroemer, M Schäfer-Korting Lehrbuch der Pharmakologie und Toxikologie 9, 2001 | 590* | 2001 |
| Chain length-specific properties of ceramides S Grösch, S Schiffmann, G Geisslinger Progress in lipid research 51 (1), 50-62, 2012 | 525 | 2012 |
| Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation F Beiche, S Scheuerer, K Brune, G Geisslinger, M Goppelt-Struebe FEBS letters 390 (2), 165-169, 1996 | 437 | 1996 |
| COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites M Burian, G Geisslinger Pharmacology & therapeutics 107 (2), 139-154, 2005 | 400 | 2005 |
| Ziconotide for treatment of severe chronic pain A Schmidtko, J Lötsch, R Freynhagen, G Geisslinger The Lancet 375 (9725), 1569-1577, 2010 | 388 | 2010 |
| Pharmacokinetics of opioids in liver disease I Tegeder, J Lötsch, G Geisslinger Clinical pharmacokinetics 37, 17-40, 1999 | 369 | 1999 |
| Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer E Ruckhäberle, A Rody, K Engels, R Gaetje, G Von Minckwitz, ... Breast cancer research and treatment 112, 41-52, 2008 | 353 | 2008 |
| Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain M Sisignano, R Baron, K Scholich, G Geisslinger Nature Reviews Neurology 10 (12), 694-707, 2014 | 321 | 2014 |
| Capturing adenylyl cyclases as potential drug targets S Pierre, T Eschenhagen, G Geisslinger, K Scholich Nature reviews Drug discovery 8 (4), 321-335, 2009 | 271 | 2009 |
| Opioids as modulators of cell death and survival—unraveling mechanisms and revealing new indications I Tegeder, G Geisslinger Pharmacological reviews 56 (3), 351-369, 2004 | 267 | 2004 |
| The IKK‐NF‐κB pathway: a source for novel molecular drug targets in pain therapy? E Niederberger, G Geisslinger The FASEB Journal 22 (10), 3432-3442, 2008 | 266 | 2008 |
| Ceramide synthases and ceramide levels are increased in breast cancer tissue S Schiffmann, J Sandner, K Birod, I Wobst, C Angioni, E Ruckhäberle, ... Carcinogenesis 30 (5), 745-752, 2009 | 263 | 2009 |
| Analgesic effects of morphine and morphine‐6‐glucuronide in a transcutaneous electrical pain model in healthy volunteers C Skarke, J Darimont, H Schmidt, G Geisslinger, J Lötsch Clinical Pharmacology & Therapeutics 73 (1), 107-121, 2003 | 260 | 2003 |
| Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives J Lötsch, C Skarke, J Liefhold, G Geisslinger Clinical pharmacokinetics 43, 983-1013, 2004 | 254 | 2004 |
| Cyclooxygenase-2 (COX-2)-dependent and-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells TJ Maier, K Schilling, R Schmidt, G Geisslinger, S Grösch Biochemical pharmacology 67 (8), 1469-1478, 2004 | 251 | 2004 |
| Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting H Dormann, U Muth-Selbach, S Krebs, M Criegee-Rieck, I Tegeder, ... Drug safety 22, 161-168, 2000 | 246 | 2000 |
